Abbonarsi

Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea - 05/06/24

Doi : 10.1016/j.jaci.2024.01.025 
Hong Jin Kim, MD, PhD a, , Min-Ho Kim, PhD b, , Seong Jun Park, MD c, Myeong Geun Choi, MD, PhD c, Eun Mi Chun, MD, PhD c,
a Department of Orthopedic Surgery, Inje University Sanggye Paik Hospital, College of Medicine, Inje University, Seoul, Korea 
b Informatization Department, Ewha Womans University Seoul Hospital, Ewha Womans University, Seoul, Korea 
c Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, School of Medicine, Ewha Womans University, Seoul, Korea 

Corresponding author: Eun Mi Chun, MD, PhD, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ewha Womans University, 1071, Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea.Division of Pulmonary and Critical Care MedicineDepartment of Internal MedicineEwha Womans University1071Anyangcheon-roYangcheon-guSeoulKorea07985

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.

Si connetta per beneficiarne

Abstract

Background

There is growing evidence that the coronavirus disease 2019 (COVID-19) vaccination can affect the regulation of the immune system, leading to the development of autoimmune diseases. However, the autoimmune adverse events (AEs) after COVID-19 vaccination remain largely unclear.

Objective

We sought to investigate the autoimmune AEs after COVID-19 vaccination from a population-based cohort in South Korea.

Methods

A total of 4,203,887 participants, representing 50% of the population residing in Seoul, were recruited from the National Health Insurance Service database and then divided into 2 groups on the basis of COVID-19 vaccination. The cumulative incidence, hazard ratios (HRs), and 95% CIs of autoimmune AEs were assessed following COVID-19 vaccination.

Results

The incidence of vitiligo has been observed to be significantly higher in the vaccination group compared with the no vaccination group. The cumulative incidence of vitiligo began to show a significant difference starting 2 weeks after vaccination, and it reached 2.2% in the vaccination group and 0.6% in the no vaccination group by 3 months after COVID-19 vaccination. Vitiligo (HR, 2.714; 95% CI, 1.777-4.146) was an increased risk among autoimmune AEs. Furthermore, the risk of vitiligo was the highest for heterologous vaccination (HR, 3.890; 95% CI, 2.303-6.573) compared with using cDNA vaccine (HR, 2.861; 95% CI, 1.838-4.453) or mRNA vaccine (HR, 2.475; 95% CI, 1.607-3.813).

Conclusions

Vitiligo as an autoimmune AE was noted to be substantially higher in the COVID-19–vaccinated group compared with the controls. Therefore, the occurrence of vitiligo could be considered as one of the significant AEs post–COVID-19 vaccination.

Il testo completo di questo articolo è disponibile in PDF.

Key words : COVID-19, vaccination, vitiligo, autoimmune adverse events, complications

Abbreviations used : AE, AIH, AS, CCI, COPD, COVID-19, DC, DM, GSEA, GTEx, HPA, HR, HT, HTN, IBD, IRB, NHIS, OR, PBC, RA, SARS-CoV-2


Mappa


© 2024  The Authors. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 153 - N° 6

P. 1711-1720 - Giugno 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Validating inborn error of immunity prevalence and risk with nationally representative electronic health record data
  • Nicholas L. Rider, Ahuva Truxton, Tracy Ohrt, Irene Margolin-Katz, Mary Horan, Harold Shin, Roger Davila, Vanessa Tenembaum, Jessica Quinn, Vicki Modell, Fred Modell, Jordan S. Orange, Almut Branner, Cynthia Senerchia
| Articolo seguente Articolo seguente
  • Joint transcriptomic and cytometric study of children with peanut allergy reveals molecular and cellular cross talk in reaction thresholds
  • Lingdi Zhang, Yoojin Chun, Zoe Arditi, Galina Grishina, Tracy Lo, Kayla Wisotzkey, Charuta Agashe, Alexander Grishin, Julie Wang, Hugh A. Sampson, Scott Sicherer, M. Cecilia Berin, Supinda Bunyavanich

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.